| 马丽芬,苏振丽,徐晶,等.小剂量阿托伐他汀钙联合苯扎贝特治疗混合型高脂血症合并高尿酸血症的临床观察[J].安徽医药,2018,22(7):1376-1379. |
| 小剂量阿托伐他汀钙联合苯扎贝特治疗混合型高脂血症合并高尿酸血症的临床观察 |
| Clinical observation of small dose of atorvastatin calcium combined with bezafibrate in treatment of mixed hyperlipidemia and hyperuricemia |
| 投稿时间：2016-06-08 |
| DOI： |
| 中文关键词: 高脂血症 高尿酸血症 苯扎贝特 羟甲基戊二酰基CoA还原酶抑制剂 |
| 英文关键词: Hyperlipidemias Hyperuricemia Bezafibrate Hydroxymethylglutaryl-CoA reductase inhibitors |
| 基金项目: |
|
| 摘要点击次数: 2664 |
| 全文下载次数: 635 |
| 中文摘要: |
| 目的 分析小剂量阿托伐他汀钙联合苯扎贝特治疗混合型高脂血症合并高尿酸血症的临床应用。方法 选取混合型高脂血症合并高尿酸血症患者111例,简单随机法分为三组,即小剂量阿托伐他汀钙37例(10 mg·d-1),苯扎贝特组37例(200 mg·d-1),小剂量阿托伐他汀钙(10 mg·d-1)联合苯扎贝特组37例(200 mg·d-1),8周为一疗程,疗程结束对比分析三组患者治疗前后总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)以及血尿酸(BUA)的变化。结果 治疗前TC、TG、LDL-C、HDL-C以及BUA在三组间比较差异无统计学意义(P>0.05)；治疗后三组间TC、TG、LDL-C以及BUA差异有统计学意义(F值分别为6.153、4.364、8.546和18.000,P分别为0.003、0.015、<0.001和<0.001),经LSD法组间两两比较结果显示联合组TC降低(2.09±0.57) mmol·L-1、TG降低(0.82±0.16) mmol·L-1、LDL-C降低(1.71±0.26) mmol·L-1 BUA降低(81.54±71.12) mmol·L-1较阿托伐他汀钙组、苯扎贝特组下降幅度更大(P<0.05)。联合组血脂改善疗效高于其它两组(χ2=7.346,P=0.025)；联合组血尿酸改善高于其它两组,差异有统计学意义(χ2=8.194,P=0.017)。阿托伐他汀钙联合苯扎贝特不良反应发生率为13.5%,其它两组均为10.8%,三组间差异无统计学意义(P>0.05)。结论 小剂量阿托伐他汀钙联合苯扎贝特可有效改善混合型高脂血症合并高尿酸血症患者的血脂以及血尿酸含量,较两者单独用药时效果显著,且联合用药未增加不良反应发生率,临床效果肯定。 |
| 英文摘要: |
| Objective Analysis of clinical application of small doses of atorvastatin calcium combined with bezafibrate in treatment of mixed hyperlipidemia and hyperuricemia. Methods A total of 111 patients with mixed hyperlipidemia and hyperuricemia in our hospital were randomly divided into 3 groups, 37 cases as small dosage of Atorvastatin (10 mg·d-1) and 37 cases as Bezafibrate group (200 mg·d-1) and 37 cases as small dosage of Atorvastatin combined with Benzene Bezafibrate group (10 mg·d-1+200 mg·d-1). At the end of 8 weeks treatment, the three groups of patients with total cholesterol (TC), and triglyceride glycerol (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and changes of blood uric acid (BUA) before and after the treatment were analyzed. Results There was no significant difference in TC(2.09±0.57) mmol·L-1, TG(0.82±0.16) mmol·L-1, LDL-C(1.71±0.26) mmol·L-1 and BUA(81.54±71.12) mmol·L-1 before treatment between the 3 groups (P>0.05). After treatment, the differences of TC, TG, LDL-C and BUA between the three groups were statistically significant (F values were 6.153,4.364,8.546 and 18, P were 0.003,0.015, <0.001 and <0.001, respectively).The TC,TG,LDL-C and BUA of the combined group was more lower than the atorvastatin group and the Bezafibrate group by the LSD method analysis(P<0.05). The combined group to improve the efficacy of blood lipid was significantly higher than the other two groups (χ2=7.346, P=0.025). The improved blood uric acid of the combined group was significantly higher than that of other two groups (χ2=8.194, P=0.017). The incidence of adverse reactions of atorvastatin calcium combined with bezafibrate was 13.5%, and the other two groups were 10.8%, incidence of adverse reactions between the 3 groups was not statistically significant difference (P> 0.05). ConclusionA small dose of Atorvastatin calcium combined with Bezafibrate can effectively improve the blood lipid of patients with mixed hyperlipidemia and hyperuricemia and blood uric acid content, compared with either drug alone has significant effect, and the combined treatment did not increase the incidence of adverse reactions and clinical effects of certain. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
